Sandra E. Kurtin, PhDc, ANP-C, AOCN, on CLL: Results From the MURANO Study

Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the first phase III prospective data on the impact of minimal residual disease on the long-term clinical outcomes with venetoclax plus rituximab vs bendamustine plus rituximab in chronic lymphocytic leukemia (Abstract 695).